Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC |
FAVUS ELLIOTDirector
|
SaleCommon Stock | 145,500 | $12.66 | $1,841,855.40 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · nonDerivative · entry 3 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC |
FAVUS ELLIOTDirector
|
Exercise / conversionCommon Stock | 100,000 | $3.28 | $328,000.00 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · nonDerivative · entry 2 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 02:31 UTC |
FAVUS ELLIOTDirector
|
Exercise / conversionCommon Stock | 45,500 | $2.58 | $117,390.00 |
DisclosureSEC source: 0001731122-21-000308 · ownership.xml · nonDerivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:22 UTC |
Donhauser Peter D.O.Director
|
PurchaseCommon Stock | 165 | $12.97 | $2,140.05 |
DisclosureSEC source: 0001731122-21-000286 · ownership.xml · nonDerivative · entry 2 Donhauser Peter D.O. · CIK 0001698234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 18:22 UTC |
Donhauser Peter D.O.Director
|
PurchaseCommon Stock | 1,000 | $12.62 | $12,620.00 |
DisclosureSEC source: 0001731122-21-000286 · ownership.xml · nonDerivative · entry 1 Donhauser Peter D.O. · CIK 0001698234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 14:17 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000004 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common stock · 550,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2/3 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:29 UTC |
Skarpelos AthanasiosDirector
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000016 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:28 UTC |
Thomas SteffenDirector
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000014 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:26 UTC |
Boenisch SandraPFO and Treasurer
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000012 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2/3 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:24 UTC |
Donhauser Peter D.O.Director
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000010 · ownership.xml · derivative · entry 1 Donhauser Peter D.O. · CIK 0001698234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:22 UTC |
FAVUS ELLIOTDirector
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000008 · ownership.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 19:20 UTC |
Velden Claus VanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001731122-21-000006 · ownership.xml · derivative · entry 1 Velden Claus Vander · CIK 0001733908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-12-30 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC |
Thomas SteffenDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000022 · ownership.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC |
Velden Claus VanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000023 · ownership.xml · derivative · entry 1 Velden Claus Vander · CIK 0001733908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 18:00 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000021 · ownership.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC |
Boenisch SandraPFO & Treasurer
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000024 · ownership.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC |
FAVUS ELLIOTDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000020 · ownership.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC |
Skarpelos AthanasiosDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000018 · ownership.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:00 UTC |
Donhauser Peter D.O.Director
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001731122-20-000019 · ownership.xml · derivative · entry 1 Donhauser Peter D.O. · CIK 0001698234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-06 Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 23:27 UTC |
Boenisch SandraPFO & Treasurer
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001213900-19-010249 · s113104_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: The options shall vest upon the achievement by the Company of 100% patient enrollment in the Company's Phase 2b/3 Alzheimer's disease and Phase 2 Parkinson's disease dementia clinical trials. Read SEC document |
| May 03, 2019 Filed May 7, 2019 16:31 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001615774-19-007213 · s118064_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common stock · 750,000 shares Expires 2029-05-03 F1 · derivative.exercise_date: The options shall vest as to 250,000 on July 5, 2020, 250,000 on July 5, 2021 and 250,000 on July 5, 2022. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:31 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 409,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010443 · s113106_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,500 Underlying: Common Stock · 409,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:33 UTC |
FAVUS ELLIOTDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010447 · s113108_form4.xml · derivative · entry 1 FAVUS ELLIOT · CIK 0001608022 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:30 UTC |
Thomas SteffenDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010441 · s113105_form4.xml · derivative · entry 1 Thomas Steffen · CIK 0001646396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:32 UTC |
Velden Claus VanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010445 · s113107_form4.xml · derivative · entry 1 Velden Claus Vander · CIK 0001733908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:29 UTC |
Boenisch SandraPFO & Treasurer
|
GrantStock Option (Right to Buy) · Derivative | 27,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010439 · s113104_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,300 Underlying: Common Stock · 27,300 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:27 UTC |
Donhauser Peter D.O.Director
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010436 · s113103_form4.xml · derivative · entry 1 Donhauser Peter D.O. · CIK 0001698234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| October 01, 2018 Filed Oct 9, 2018 20:42 UTC |
Skarpelos AthanasiosDirector
|
GrantStock Option (Right to Buy) · Derivative | 45,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001615774-18-010620 · s113196_form4.xml · derivative · entry 1 Skarpelos Athanasios · CIK 0001360570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Underlying: Common Stock · 45,500 shares Expires 2028-10-01 F1 · derivative.exercise_date: The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials. Read SEC document |
| May 15, 2018 Filed May 17, 2018 17:16 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001615774-18-004019 · s110299_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The options shall vest upon the achievement of certain performance criteria in connection with clinical trial milestones. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:23 UTC |
Boenisch SandraPFO & Treasurer
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001615774-18-004023 · s110300_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The options shall vest upon the achievement of certain performance criteria in connection with clinical trial milestones. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 15:16 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 1,360 | $2.92 | $3,971.20 |
DisclosureSEC source: 0001615774-18-001744 · s109283_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,210 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 11:01 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 1,450 | $2.73 | $3,958.50 |
DisclosureSEC source: 0001615774-18-001650 · s109262_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016,850 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 14:06 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 1,500 | $2.63 | $3,945.00 |
DisclosureSEC source: 0001615774-18-001629 · s109254_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,400 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 08:56 UTC |
MISSLING CHRISTOPHER UDirector · Director, President & CEO
|
PurchaseCommon Stock | 1,650 | $2.41 | $3,976.50 |
DisclosureSEC source: 0001615774-18-001587 · s109234_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · Director, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013,900 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:09 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001615774-17-007355 · s108449_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: The options shall vest quarterly over a three-year period commencing on March 31, 2018. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:11 UTC |
Boenisch SandraPFO & Treasurer
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001615774-17-007357 · s108450_form4.xml · derivative · entry 1 Boenisch Sandra · CIK 0001655366 · PFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: The options shall vest quarterly over a three-year period commencing on March 31, 2018. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 14:49 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.39 | $1,646.25 |
DisclosureSEC source: 0001615774-17-005929 · s107870_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,250 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 24, 2017 Filed Oct 24, 2017 12:05 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.92 | $1,845.00 |
DisclosureSEC source: 0001615774-17-005861 · s107842_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,875 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 19, 2017 Filed Oct 19, 2017 18:46 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.49 | $1,683.75 |
DisclosureSEC source: 0001615774-17-005807 · s107803_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,500 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 09:46 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.27 | $1,601.25 |
DisclosureSEC source: 0001615774-17-005767 · s107769_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,125 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 13, 2017 Filed Oct 16, 2017 11:06 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 750 | $4.22 | $3,165.00 |
DisclosureSEC source: 0001615774-17-005731 · s107755_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,750 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 17:56 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.30 | $1,612.50 |
DisclosureSEC source: 0001615774-17-005604 · s107704_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010,000 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 19:52 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.20 | $1,575.00 |
DisclosureSEC source: 0001615774-17-005508 · s107663_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,625 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 14:31 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.21 | $1,578.75 |
DisclosureSEC source: 0001615774-17-005440 · s107643_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,250 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 26, 2017 Filed Sep 26, 2017 15:07 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $3.88 | $1,455.00 |
DisclosureSEC source: 0001615774-17-005351 · s107605_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,875 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 20, 2017 Filed Sep 20, 2017 16:50 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.23 | $1,586.25 |
DisclosureSEC source: 0001615774-17-005226 · s107562_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,500 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 18, 2017 Filed Sep 19, 2017 13:58 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.40 | $1,650.00 |
DisclosureSEC source: 0001615774-17-005183 · s107540_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,125 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 14:27 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.58 | $1,717.50 |
DisclosureSEC source: 0001615774-17-005088 · s107514_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,750 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 11, 2017 Filed Sep 11, 2017 20:49 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.81 | $1,803.75 |
DisclosureSEC source: 0001615774-17-005014 · s107463_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,375 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 19:20 UTC |
MISSLING CHRISTOPHER UDirector · President and CEO
|
PurchaseCommon Stock | 375 | $4.76 | $1,785.00 |
DisclosureSEC source: 0001615774-17-004994 · s107446_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,000 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.